Nasus Pharma is trading 5.01% up at $3.65, with no new company-specific announcement explaining the September 28 move found in available search results.

  • The FDA clearance for its NS002 clinical study was announced September 14, well before this session.
  • Reuters reported global stocks fell as oil rose amid stalled U.S.-Iran talks and Treasury yields climbed. This risk-off backdrop runs counter to Nasus Pharma’s gain and does not establish why the stock is rising.